SML0335
Remacemide hydrochloride
≥98% (HPLC)
别名:
2-Amino-N-(1-methyl-1,2-diphenylethyl)-acetamide hydrochloride, FPL 12924AA, PR 934-423A
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C17H20N2O · HCl
化学文摘社编号:
分子量:
304.81
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
InChI
1S/C17H20N2O.ClH/c1-17(19-16(20)13-18,15-10-6-3-7-11-15)12-14-8-4-2-5-9-14;/h2-11H,12-13,18H2,1H3,(H,19,20);1H
SMILES string
Cl.CC(Cc1ccccc1)(NC(=O)CN)c2ccccc2
InChI key
HYQMIUSWZXGTCC-UHFFFAOYSA-N
assay
≥98% (HPLC)
form
powder
storage condition
desiccated
color
white to beige
solubility
H2O: >10 mg/mL
storage temp.
room temp
Quality Level
Biochem/physiol Actions
Remacemide HCl is a low affinity NMDA antagonist with anticonvulsant properties.
Remacemide HCl is a low affinity NMDA antagonist with anticonvulsant properties. Remacemide also been shown to block voltage-dependent sodium channels.
Remacemide possesses neuroprotective and anti-epileptic actions. It supports reducing the frequency of seizures. Remacemide is also known to be a potential therapeutic for Huntington′s disease.
Features and Benefits
This compound is featured on the Glutamate Receptors (Ion Channel Family) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Aquatic Acute 1 - Eye Dam. 1
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Robert Małek et al.
Polish journal of pharmacology, 55(5), 691-698 (2004-01-06)
Epilepsy belongs to common diseases of the brain. It affects approximately 1% of the population. The aim of epilepsy therapy is to keep the patient free of seizures without interfering with normal brain function. Unfortunately, about 30% of all epilepsies
Gabriele Schilling et al.
Experimental neurology, 187(1), 137-149 (2004-04-15)
The HD-N171-82Q (line 81) mouse model of Huntington's disease (HD), expresses an N-terminal fragment of mutant huntingtin (htt), loses motor function, displays HD-related pathological features, and dies prematurely. In the present study, we compare the efficacy with which environmental, pharmacological
D Chadwick et al.
Seizure, 9(8), 544-550 (2001-02-13)
Forty patients (33 male, 7 female) with refractory epilepsy were randomized to receive ascending weekly doses of adjunctive remacemide hydrochloride in a b.i.d. or q.i.d. regimen, or placebo for up to 1 month. Assessments included routine physical examination and laboratory
E H Aylward et al.
Brain research bulletin, 62(2), 137-141 (2003-11-26)
Previous research has demonstrated that longitudinal change in caudate volume could be observed over a period of 3 years in subjects with Huntington's disease (HD). The current pilot study was designed to determine whether measurement of caudate change on magnetic
M W Jones et al.
Seizure, 11(2), 104-113 (2002-04-12)
Remacemide hydrochloride is a low-affinity, non-competitive NMDA receptor channel blocker under investigation for the treatment of epilepsy. This double-blind, placebo-controlled, multicentre study assessed the safety and efficacy of adjunctive remacemide hydrochloride or placebo, in adult patients with refractory epilepsy who
商品
We offers many products related to ion channel family glutamate receptors for your research needs.
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持